Lead Product(s) : Tvb-2640
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : Tvb-2640
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tvb-2640
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Sagimet Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Tvb-2640
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Sagimet Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tvb-2640
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Tvb-2640
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tvb-2640
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : Tvb-2640
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tvb-2640
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2019
Lead Product(s) : Tvb-2640
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tvb-2640
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Sagimet Biosciences | Cancer Prevention Research Institute of Texas | Gateway for Cancer Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2019
Lead Product(s) : Tvb-2640
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Sagimet Biosciences | Cancer Prevention Research Institute of Texas | Gateway for Cancer Research
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2014